NovoCure touts JAMA publication of Optune trial data

NovoCure (NSDQ:NVCR) said today data from the pivotal phase 3 trial of its Optune device, in combination with standard-of-care temozolomide, for treating newly diagnosed glioblastoma has been published in the Journal of the American Medical Association. The results from the EF-14 trial reported that Optune along with temozolomide significantly extended progression-free survival and overall survival compared to temozolomide alone in treating newly diagnosed glioblastoma. “The EF-14 data are spectacular. They support Tumor Treating Fields as a new standard of care for patients suffering from glioblastoma. These results establish a proof-of-principle of an entirely new cancer treatment modality,” principal investigator Dr. Roger Stupp of Switzerland’s University of Zurich said in prepared remarks. Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death. “We are pleased the EF-14 trial results have been published in JAMA, one of the most highly recognized and respected peer-reviewed medical journals. We believe the data will give physicians even greater confidence in the value and importance of Optune as an effective and safe treatment option for newly diagnosed GBM patients. We believe EF-14 is the first trial in glioblastoma to be stopped at the interim analysis because of clear superiorit...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Oncology Clinical Trials NovoCure Source Type: news